Retinal ganglion cell genome (RGC genome)

The retinal ganglion cell (RGC) genome represents the complete set of genetic information within the neurons that transmit visual signals from the retina to the brain (Source: NIH/National Eye Institute). While not a single protein or receptor, the RGC genome is the focus of advanced therapeutic interventions, particularly gene therapies and genome editing, aimed at treating blinding diseases (Source: PubMed, PMID: 31554014). Mutations within specific genes of the RGC genome, such as MT-ND4 in Leber Hereditary Optic Neuropathy (LHON) or OPA1 in autosomal dominant optic atrophy, result in the progressive degeneration of RGCs and their axons (Source: UniProt). Therapeutic strategies like Lumevoq (lenadogene nolparvovec) utilize viral vectors to deliver functional gene copies directly into the RGC environment to restore mitochondrial function and prevent cell death (Source: GenSight Biologics). Additionally, research into CRISPR-based editing of the RGC genome seeks to silence or correct mutations associated with glaucoma, such as those in the MYOC gene (Source: PubMed, PMID: 28461350). Consequently, the RGC genome serves as a critical landscape for neuroprotective and regenerative medicine in ophthalmology.

Other names

Retinal ganglion cell DNARGC genetic materialRetinal ganglion cell genomic DNA

Gene replacement therapy, CRISPR/Cas9-mediated gene editing, and RNA interference (RNAi) targeting specific loci within the RGC genome to restore protein function or reduce toxic gain-of-function (Source: PubMed, PMID: 31554014).